Literature DB >> 6197450

Complement activation via the alternative pathway by purified Salmonella lipopolysaccharide is affected by its structure but not its O-antigen length.

N Grossman, L Leive.   

Abstract

Salmonellae, the lipopolysaccharide of which differ in the chemical structure of their O-antigenic side chains, were previously shown to activate C3 at differential rates via the alternative pathway. We wanted to test whether lipopolysaccharide isolated from these strains yields identical results, and also the effect of the polysaccharide chain length, which varies from 0 to 40 or more repeating units in a single strain. Lipopolysaccharide was purified from the above strains, hydrolyzed (0.1 N NaOH, 56 degrees C, 30 min), and used to coat sheep erythrocytes to different densities, and C3 activation in C4-deficient guinea pig serum was measured. C3 activation was proportional to lipopolysaccharide density and time, and the relative rates and extents of activation by this bacteria-free system were the same as for the original bacteria. Activation was reduced 10 to 15% when the serum was preabsorbed with strains either containing or lacking O-antigen side chain, suggesting augmentation by antibody; however, even after multiple absorptions, activation varied with O-antigen structure as expected. This differential activation was not due to differences in the average length of the O-antigenic polysaccharide chains, because the size was similar for all three lipopolysaccharides. Moreover, the extent of activation by lipopolysaccharide that had been fractionated on a column of Sephadex G-200 was independent of the polysaccharide chain length for lengths greater than 3 repeating units. The results prove that C3 activation by lipopolysaccharide via the alternative pathway is sensitive to slight variations in the chemical structure, but not to large variations in length of the O-antigen polysaccharide side chain of lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197450

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

2.  Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii.

Authors:  S Vishwanath; T Hackstadt
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

3.  Interactions of F1 fractions from different strains of Paracoccidioides brasiliensis with human complement and with human neutrophils.

Authors:  L S Crott; Y M Lucisano-Valim; C L Silva; J E Barbosa
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

4.  Comparative pathogenicity of different Actinobacillus suis O/K serotypes.

Authors:  D Slavić; J DeLay; M A Hayes; J I MacInnes
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

5.  In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.

Authors:  Seth J Rotz; Nathan Luebbering; Bradley P Dixon; Eleni Gavriilaki; Robert A Brodsky; Christopher E Dandoy; Sonata Jodele; Stella M Davies
Journal:  Blood Adv       Date:  2017-08-23

Review 6.  Complement resistance in microbes.

Authors:  M C Moffitt; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Bactericidal and opsonizing effects of normal serum on mutant strains of Salmonella typhimurium.

Authors:  M F Shaio; H Rowland
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

Review 8.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

9.  Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Authors:  A Sahu; T R Kozel; M K Pangburn
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

10.  Cercarial glycocalyx of Schistosoma mansoni activates human complement.

Authors:  J C Samuelson; J P Caulfield
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.